Standard BioTools Inc (LAB) Actualités

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Standard BioTools to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today...

Form 8-K - Current report

Standard BioTools Reports Fourth Quarter and Full Year 2024 Financial Results

SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the...

Form 4 - Statement of changes in beneficial ownership of securities

Standard BioTools Schedules Fourth Quarter and Full Year 2024 Earnings Conference Call on February 26, 2025

SOUTH SAN FRANCISCO, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today...

Form 8-K - Current report

Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2024 Revenue

 Preliminary, unaudited revenue for the full year 2024 of approximately $174 million Presenting at the 43rd...

Form 8-K - Current report

Standard BioTools SomaScan Assay Powers Key Insights into Semaglutide Treatment Published in Nature Medicine

SOUTH SAN FRANCISCO, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the...

Form 8-K - Current report

Standard BioTools to Present at the 43rd Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today...

Form 4 - Statement of changes in beneficial ownership of securities